HC Wainwright Forecasts Lower Earnings for Niagen Bioscience

Niagen Bioscience, Inc. (NASDAQ:NAGE) – HC Wainwright reduced their Q3 2025 EPS estimates for shares of Niagen Bioscience in a note issued to investors on Monday, August 11th. HC Wainwright analyst R. Selvaraju now expects that the company will earn $0.02 per share for the quarter, down from their prior estimate of $0.05. HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. HC Wainwright also issued estimates for Niagen Bioscience’s Q4 2025 earnings at $0.02 EPS, FY2025 earnings at $0.15 EPS, Q1 2026 earnings at $0.07 EPS and Q4 2026 earnings at $0.13 EPS.

Niagen Bioscience (NASDAQ:NAGE) last released its quarterly earnings data on Wednesday, August 6th. The company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.02. Niagen Bioscience had a return on equity of 23.12% and a net margin of 15.24%. The firm had revenue of $31.12 million for the quarter, compared to analyst estimates of $28.55 million.

Several other equities analysts also recently commented on NAGE. Canaccord Genuity Group upped their price objective on shares of Niagen Bioscience from $13.00 to $16.00 and gave the company a “buy” rating in a report on Tuesday, June 10th. Wall Street Zen raised shares of Niagen Bioscience from a “buy” rating to a “strong-buy” rating in a report on Saturday. Finally, Roth Capital reissued a “buy” rating and issued a $23.00 price target (up from $10.00) on shares of Niagen Bioscience in a report on Friday, June 6th. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $13.42.

Niagen Bioscience Trading Up 3.2%

NAGE stock opened at $10.02 on Thursday. The business’s 50 day simple moving average is $11.57 and its 200 day simple moving average is $8.43. Niagen Bioscience has a 1-year low of $3.10 and a 1-year high of $14.69. The firm has a market capitalization of $799.13 million, a PE ratio of 47.72 and a beta of 2.12.

Institutional Trading of Niagen Bioscience

Several hedge funds and other institutional investors have recently bought and sold shares of the business. State of Wyoming acquired a new position in shares of Niagen Bioscience during the 4th quarter worth approximately $39,000. Mercer Global Advisors Inc. ADV acquired a new stake in Niagen Bioscience during the fourth quarter worth approximately $53,000. Schonfeld Strategic Advisors LLC bought a new position in Niagen Bioscience during the 4th quarter worth $67,000. ProShare Advisors LLC acquired a new position in Niagen Bioscience in the 4th quarter valued at $74,000. Finally, Sherbrooke Park Advisers LLC acquired a new position in Niagen Bioscience in the 4th quarter valued at $94,000. Institutional investors and hedge funds own 15.41% of the company’s stock.

About Niagen Bioscience

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.